• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Life Science Market
Life Science News
Life Science Stocks
  • Life Science Market
  • Life Science News
  • Life Science Stocks
life science investing

Price of Drug Used to Treat Heroin Overdoses on the Rise

Charlotte McLeod
Mar. 09, 2015 04:34PM PST
Life Science Investing

The Associated Press reported that advocates are worried that the rising price of naloxone could lead to the death of heroin addicts.

The Associated Press reported that advocates are worried that the rising price of naloxone could lead to the death of heroin addicts. The drug, which is often sold in the US under the brand name Narcan, is used as an antidote to heroin overdoses.

As quoted in the market news:

Officials across the country have largely agreed that it makes sense to hand out naloxone to police, families of addicts and drug users themselves, and in some places are now scrambling to negotiate discounts for programs that buy it in bulk for public distribution.

JSAS HealthCare, a clinic based on the New Jersey shore, began last year training community members to administer the drug and providing it to them with the help of state funds.

But a price increase late last year means that instead of buying 400 naloxone kits for a little under $21,000 — at $51.50 per kit paid to a third-party distribution company — that’s now enough for only 200, at just under $100 per kit, a negotiated discount that’s $5 cheaper than what he was quoted.

Jason Shandell, president of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH), which sells a popular naloxone product, commented:

Like other companies in the industry, manufacturing costs for our entire portfolio of products, including naloxone, have been steadily increasing due to the continued rise in costs for raw materials, energy, and labor over the recent several years.

Click here to read the full report from The Associated Press.

life science investing
The Conversation (0)

Go Deeper

AI Powered
NextSource Materials Announces Preliminary Economic Assessment for a Mine Expansion of 150,000 Tonnes per Annum of SuperFlake Graphite Concentrate

NextSource Materials Announces Preliminary Economic Assessment for a Mine Expansion of 150,000 Tonnes per Annum of SuperFlake Graphite Concentrate

6 Opioid Use Disorder Treatment Stocks

6 Opioid Use Disorder Treatment Stocks

Latest News

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

U.S. Patent allowance received for PTSD discovery programme

Seegnal's operating subsidiary Seegnal E-Health Ltd. hires AI VP to Strengthen AI Capabilities and Accelerates Development of Seegnal Guard

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Life Science Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES